Routine board compensation issuance with negligible dilution — no trading catalyst. Monitor the Phase 2b ASPIRE trial data readout for buloxibutid as the next material event.
Price Chart
Executive Summary
Vicore Pharma issued 118,916 new shares via warrant exercises under Board LTIP 2023/2024 and Board RSU 2025 incentive programs, increasing total shares and votes to 281,644,509. The dilution is minimal (~0.04% of outstanding shares) and relates to routine board compensation — no material impact on fundamentals or the ongoing Phase 2b ASPIRE trial for buloxibutid.
Key Facts
- 118,916 new shares issued from exercise of 117,737 share awards under Board LTIP 2023, Board LTIP 2024, and Board RSU 2025 programs
- Total registered shares and votes increased to 281,644,509
- Share capital increased by 59,457.999424 SEK
- Dilution represents approximately 0.04% of outstanding shares
Financial Impact
Minimal dilution of ~0.04% of outstanding shares; no cash proceeds disclosed
Risk Factors
- No material risks from this filing; clinical trial execution risk remains the primary concern
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-031613 |
| Exhibit: ex_1020801.htm | 0001437749-26-031613 |
| Document: 0001437749-26-031613-index-headers.html | 0001437749-26-031613 |
| Document: 0001437749-26-031613-index.html | 0001437749-26-031613 |
| Document: 0001437749-26-031613.txt | 0001437749-26-031613 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $9.38 $9.40 | ▲ +0.21% | ▼ −0.50% | $9.40 (+0.21%) |
Oct 13, 2026 14d ago | SC 13G | $9.08 $9.09 | ▲ +0.11% | ▼ −0.17% | $9.40 (+3.52%) |
Sep 30, 2026 27d ago | 6-K | $9.43 $9.33 | ▼ −1.06% | ▼ −1.80% | $9.40 (−0.32%) |
Jul 6, 2026 16w ago | 6-K | $16.25 $15.03 | ▼ −7.54% | ▼ −7.06% | $9.40 (−42.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers